Tigermed Consulting to Invest 200 Million Yuan in Shanghai Sansheng Healthcare Private Equity Fund

Stock News06-02 19:26

Hangzhou Tigermed Consulting Co.,Ltd. has announced its intention to participate in an investment fund.

The company plans to invest through its entity, Hangzhou Tigermed Equity Investment Partnership, in the Shanghai Sansheng Healthcare Private Equity Investment Fund Partnership.

The initial total committed capital for this fund is set at 950 million yuan.

Hangzhou Tigermed Consulting Co.,Ltd. (ASX: 300347)

Tigermed's investment vehicle will contribute 200 million yuan of its own capital as a limited partner in the fund.

The fund's investment strategy will concentrate on sectors including innovative drugs and advanced formulations, high-end medical devices, biotechnology, and sophisticated pharmaceutical equipment.

Establishing this industry-focused fund allows the company to leverage its specialized expertise in the biopharma and healthcare sector.

This move is aimed at broadening the company's investment avenues and generating investment returns.

The collaborative model is also expected to enhance the company's overall service capabilities and help develop a pipeline of high-quality projects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160726976?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160726976","market":"hk","top_or_hot":-1,"title":"Tigermed Consulting to Invest 200 Million Yuan in Shanghai Sansheng Healthcare Private Equity Fund","media":"Stock News","content":"<p>Hangzhou Tigermed Consulting Co.,Ltd. has announced its intention to participate in an investment fund.<br><br>The company plans to invest through its entity, Hangzhou Tigermed Equity Investment Partnership, in the Shanghai Sansheng Healthcare Private Equity Investment Fund Partnership.<br><br>The initial total committed capital for this fund is set at 950 million yuan.<br><br><b>Hangzhou Tigermed Consulting Co.,Ltd. (ASX: 300347)</b><br><br>Tigermed's investment vehicle will contribute 200 million yuan of its own capital as a limited partner in the fund.<br><br>The fund's investment strategy will concentrate on sectors including innovative drugs and advanced formulations, high-end medical devices, biotechnology, and sophisticated pharmaceutical equipment.<br><br>Establishing this industry-focused fund allows the company to leverage its specialized expertise in the biopharma and healthcare sector.<br><br>This move is aimed at broadening the company's investment avenues and generating investment returns.<br><br>The collaborative model is also expected to enhance the company's overall service capabilities and help develop a pipeline of high-quality projects.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tigermed Consulting to Invest 200 Million Yuan in Shanghai Sansheng Healthcare Private Equity Fund</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTigermed Consulting to Invest 200 Million Yuan in Shanghai Sansheng Healthcare Private Equity Fund\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-02 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Tigermed Consulting Co.,Ltd. has announced its intention to participate in an investment fund.<br><br>The company plans to invest through its entity, Hangzhou Tigermed Equity Investment Partnership, in the Shanghai Sansheng Healthcare Private Equity Investment Fund Partnership.<br><br>The initial total committed capital for this fund is set at 950 million yuan.<br><br><b>Hangzhou Tigermed Consulting Co.,Ltd. (ASX: 300347)</b><br><br>Tigermed's investment vehicle will contribute 200 million yuan of its own capital as a limited partner in the fund.<br><br>The fund's investment strategy will concentrate on sectors including innovative drugs and advanced formulations, high-end medical devices, biotechnology, and sophisticated pharmaceutical equipment.<br><br>Establishing this industry-focused fund allows the company to leverage its specialized expertise in the biopharma and healthcare sector.<br><br>This move is aimed at broadening the company's investment avenues and generating investment returns.<br><br>The collaborative model is also expected to enhance the company's overall service capabilities and help develop a pipeline of high-quality projects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格医药","start_time":0,"source_url":"","article_id":"1160726976","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160726976","pubTimestamp":1780399601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hangzhou Tigermed Consulting Co.,Ltd. has announced its intention to participate in an investment fund.The company plans to invest through its entity, Hangzhou Tigermed Equity Investment Partnership,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","300347":"泰格医药","03347":"泰格医药","BK0216":"研究试验","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0028":"国家队","09939":"开拓药业-B","BK1515":"抗疫概念","BK1583":"高瓴概念","BK1161":"生物科技","BK0174":"增持","BK0077":"质押式回购","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK1574":"生物医药B类股","BK1576":"医药外包概念","BK1141":"生命科学工具和服务"},"translate_title":"泰格医药咨询2亿元入股上海三生医疗私募基金","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"300347":1,"09939":1,"03347":1},"content_text":"Hangzhou Tigermed Consulting Co.,Ltd. has announced its intention to participate in an investment fund.The company plans to invest through its entity, Hangzhou Tigermed Equity Investment Partnership, in the Shanghai Sansheng Healthcare Private Equity Investment Fund Partnership.The initial total committed capital for this fund is set at 950 million yuan.Hangzhou Tigermed Consulting Co.,Ltd. (ASX: 300347)Tigermed's investment vehicle will contribute 200 million yuan of its own capital as a limited partner in the fund.The fund's investment strategy will concentrate on sectors including innovative drugs and advanced formulations, high-end medical devices, biotechnology, and sophisticated pharmaceutical equipment.Establishing this industry-focused fund allows the company to leverage its specialized expertise in the biopharma and healthcare sector.This move is aimed at broadening the company's investment avenues and generating investment returns.The collaborative model is also expected to enhance the company's overall service capabilities and help develop a pipeline of high-quality projects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160726976","isCrawlerRequest":true}